Ascendia

  MARKET NEWS

Ofichem Expands Drug Substance Capabilities With Acquisition of Meribel Pharma Solutions’ Uppsala Site in Sweden
Centauri Therapeutics Receives an Additional $5.1 Million From CARB-X to Progress ABX-01 Lead Compound to First-in-Human Clinical Trials
BriaPro Therapeutics Files Patent Application for Immuno-Oncology Platform With Novel Multitargeting Agents
Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease
Breakthrough Study From UCLA Demonstrates Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
LENZ Therapeutics Announces NMPA Submission of ND for LNZ100 for Presbyopia Treatment
Radiopharm Theranostics Receives IND Approval  to Initiate Phase 1 Therapeutic Clinical Study to Target B7H3 With Betabart
Deciphera Announces Positive CHMP Opinion for ROMVIMZA for the Treatment of Tenosynovial Giant Cell Tumor
Inmagene Biopharmaceuticals Announces Completion of Merger With Ikena Oncology & Concurrent Private Placement of $75 Million
Simtra BioPharma Solutions Announces Strategic Purchase to Expand US Manufacturing Capacity for Injectable Medicines

  EXPERT CONTENT & RESOURCES

Kindeva e-Book: A Bridge to the Future: Our World-Class Site in Bridgeton

Kindeva e-Book: A Bridge to the Future: Our World-Class Site in Bridgeton

In this e-Book, you will learn about, the integrated capabilities of Bridgeton, MO, which eliminate the risks of fragmentation, the breadth of projects that Kindeva can support, our continuous investment in the facility to ensure it meets today’s demands and the needs of tomorrow, and the benefits of partnering with Kindeva.

EXECUTIVE INTERVIEW - Plus Therapeutics: Advancing Targeted Radiotherapeutics for Rare & Difficult-to-Treat Cancers

EXECUTIVE INTERVIEW - Plus Therapeutics: Advancing Targeted Radiotherapeutics for Rare & Difficult-to-Treat Cancers

Dr. Marc Hedrick, CEO of Plus Therapeutics, discusses the company’s targeted radiotherapeutic platform for central nervous system and solid tumor cancers and why internal radiation therapy offers patients a more advanced drug delivery solution compared to traditional external radiation therapy.

Understanding the Foundation of LNP Formulation Success

Understanding the Foundation of LNP Formulation Success

Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….

  FEATURED EDITORIAL

  COMPANY PROFILE

H&T Presspart is a market leading developer and manufacturer of drug delivery devices and components with more than 50 years’ experience and enjoys a worldwide reputation for competence, quality, and innovation in the pharmaceutical market. With a wide portfolio of components, device solutions and services, H&T Presspart partners to deliver exceptional customer experience and accelerated routes to market of customers’ drug-device programs.  H&T Presspart has 4 European manufacturing sites in Germany, Spain, Switzerland, and the UK and has sales representation in China, India, the U.S.A., and Uruguay. Click here for more.

  WHITEPAPERS & WEBINARS

vytal webinar

WEBINAR - Vytal: The RTU Snap-Fit System for Container Closure Solutions – Setting the Standard for the Future

In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..

  WHITEPAPERS & WEBINARS

Technical Brief: Mucoadhesive Polymers in Pharmaceutical Formulations

Technical Brief: Mucoadhesive Polymers in Pharmaceutical Formulations

Mucoadhesion Matters

And so does your choice of mucoadhesive polymer.

This technical brief will cover the use of polymers in a variety of dosage forms (buccal/sublingual tablets, liquid, semi-solid formulations, and oral care products) to impart mucoadhesion. The basic mechanism …

WHITEPAPER - OXYCAPT™: Multilayer Plastic Vial: An Optimal Primary Container for Drug Products Transported With Dry Ice

WHITEPAPER - OXYCAPT™: Multilayer Plastic Vial: An Optimal Primary Container for Drug Products Transported With Dry Ice

Providing Ideal Protection for Invaluable Drug Products, Including Cell and Gene Therapy Products

Product Introduction of OXYCAPT™

OXYCAPT™ is a multilayer plastic vial and syringe, consisting of three layers made from two types of resins.  The drug contact layer and …

ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products

ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products

A clear standard for identifying APIs susceptible to Nitrosamine Drug Substance-Related Impurities (NDSRI) formation has been elusive—until now. Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs. Discover how this innovative approach …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 6 – Injection Devices
August 13 – Lyophilization Manufacturing